Evidence map›Paper›PMID 27390596›Full record

ArticleJournal of Cancer2016

Clinical Significance of "Double-hit" and "Double-protein" expression in Primary Gastric B-cell Lymphomas.

Miaoxia He, Keting Chen, Suhong Li, Shimin Zhang, Jianming Zheng, Xiaoxia Hu, Lei Gao, Jie Chen, Xianmin Song, Weiping Zhang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Heterogeneity in primary gastrointestinal DLBCL: from clinical management to molecular mechanisms and treatment strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.International journal of molecular sciences · 2024
    Review
  5. Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment.Cancer control : journal of the Moffitt Cancer Center
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Miaoxia He1. Department of Pathology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, CHINA; 2. Molecular Pathology, Cellular & Molecular Pathology Branch, National Institutes of Health, Research Triangle Park, NC 27709, USA.
Keting Chen3. Department of Hematology, Changhai Hospital, The Second Military Medical University, University, Shanghai 200433, CHINA.
Suhong Li4. Department of Pathology, Children Hospital and Women Health Center of Shanxi, Taiyuan 030013, CHINA.
Shimin Zhang5. Division of Molecular Pathology, Joint Pathology Center, Washington, DC 20817, USA.
Jianming Zheng1. Department of Pathology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, CHINA.
Xiaoxia Hu3. Department of Hematology, Changhai Hospital, The Second Military Medical University, University, Shanghai 200433, CHINA.
Lei Gao3. Department of Hematology, Changhai Hospital, The Second Military Medical University, University, Shanghai 200433, CHINA.
Jie Chen3. Department of Hematology, Changhai Hospital, The Second Military Medical University, University, Shanghai 200433, CHINA.
Xianmin Song3. Department of Hematology, Changhai Hospital, The Second Military Medical University, University, Shanghai 200433, CHINA.
Weiping Zhang3. Department of Hematology, Changhai Hospital, The Second Military Medical University, University, Shanghai 200433, CHINA.
Jianmin Wang3. Department of Hematology, Changhai Hospital, The Second Military Medical University, University, Shanghai 200433, CHINA.
Jianmin Yang3. Department of Hematology, Changhai Hospital, The Second Military Medical University, University, Shanghai 200433, CHINA.
Changhai Hospital · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsPrimary gastric B-cell lymphoma is the second most common malignancy of the stomach. There are many controversial issues about its diagnosis, treatment and clinical management. "Double-hit" and "double-protein" involving gene rearrangement and protein expression of c-Myc and bcl2/bcl6 are the most used terms to describe DLBCL poor prognostic factors in recent years. However, very little is known about the role of these prognostic factors in primary gastric B-cell lymphomas. This study aims to obtain a molecular pathology prognostic model of gastric B-cell lymphoma for clinical stratified management by evaluating how the "double-hit" and "double-protein" in tumor cells as well as microenvironmental reaction of tumor stromal tissue affect clinical outcome in primary gastric B-cell lymphomas.

methodsData and tissues of 188 cases diagnosed with gastric B-cell lymphomas were used in this study. Tumor tissue microarray (TMA) of formalin fixed and paraffin embedded (FFPE) tissues was constructed for fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) analysis with a serial of biomarkers containing MYC, BCL2, BCL6, CD31, SPARC, CD10, MUM1 and Ki-67. Modeled period analysis was used to estimate 3-year and 5-year overall survival (OS) and disease-free survival (DFS) distributions.

resultsThere was no definite "double-hit" case though the gene rearrangement of c-Myc (5.9%), bcl2 (0.1%) and bcl6 (7.4%) was found in gastric B-cell lymphomas. The gene amplification or copy gains of c-Myc (10.1%), bcl-2 (17.0%) and bcl-6 (0.9%) were present in these lymphomas. There were 12 cases of the lymphomas with the "double-protein" expression of MYC and BCL2/BCL6. All patients with "double-protein" gastric B-cell lymphomas had poor outcome compared with those without. More importantly, "MYC-BCL2-BCL6" negative group of gastric B-cell lymphoma patients had favorable clinical outcome regardless clinical stage, pathological types and therapeutic modalities. And the similar better prognosis was found in the cases with low microvessel density (MVD) in tumor tissue and high expression of SPARC (SPARC≥5%) in stromal cells.

conclusions"Double-hit" lymphoma was rare among primary gastric lymphoma, while patients with multiple gene amplification and/or copy gains of c-Myc, bcl2 and bcl6, and "double-protein" gastric B-cell lymphomas had a poor clinical outcome. In addition, patients with MYC, BCL2 and BCL6 expression negative or low MVD in tumor tissue with high expression of SPARC in stromal cells could have better prognosis than other gastric B-cell lymphomas regardless of their clinical stage and pathological types. These results would be of very importance for clinical stratified management and precision medicine of gastric B-cell lymphomas.

Indexed as

Double-hitDouble-proteinFluorescent in situ hybridizationImmunohistochemistry and Tumor tissue microarray.MVDPrimary gastric B-cell lymphomaSPARC

Identifiers

PMID27390596
PMCPMC4934029
OpenAlexW2471085173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.